← Back to Discover
GREAT POINT PARTNERS LLC
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $529,120,900
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- ABIVAX SA · SPONSORED ADS · 00370M103 · shares · CALL: $53,304,000
- VOR BIOPHARMA INC · COM NEW · 929033207 · shares: $31,297,000
- ABIVAX SA · SPONSORED ADS · 00370M103 · shares: $27,226,884
- IMMUNITYBIO INC · COM · 45256X103 · shares · PUT: $26,272,004
- VERA THERAPEUTICS INC · CL A · 92337R101 · shares: $25,781,873
- ZURA BIO LTD · CLASS A ORD SHS · G9TY5A101 · shares: $24,873,987
- ALUMIS INC · COM · 022307102 · shares: $24,089,557
- SOL-GEL TECHNOLOGIES LTD · SHS NEW · M8694L137 · shares: $20,341,273
- ULTRAGENYX PHARMACEUTICAL IN · COM · 90400D108 · shares · PUT: $20,034,000
- DEFINIUM THERAPEUTICS INC · COM SHS · 24477V105 · shares: $19,992,000
Reported holdings
42 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| ABIVAX SA | SPONSORED ADS | 00370M103 | CALL | 400,000 shares | $53,304,000 |
| VOR BIOPHARMA INC | COM NEW | 929033207 | — | 1,700,000 shares | $31,297,000 |
| ABIVAX SA | SPONSORED ADS | 00370M103 | — | 204,314 shares | $27,226,884 |
| IMMUNITYBIO INC | COM | 45256X103 | PUT | 3,000,800 shares | $26,272,004 |
| VERA THERAPEUTICS INC | CL A | 92337R101 | — | 600,836 shares | $25,781,873 |
| ZURA BIO LTD | CLASS A ORD SHS | G9TY5A101 | — | 4,215,930 shares | $24,873,987 |
| ALUMIS INC | COM | 022307102 | — | 856,061 shares | $24,089,557 |
| SOL-GEL TECHNOLOGIES LTD | SHS NEW | M8694L137 | — | 274,363 shares | $20,341,273 |
| ULTRAGENYX PHARMACEUTICAL IN | COM | 90400D108 | PUT | 600,000 shares | $20,034,000 |
| DEFINIUM THERAPEUTICS INC | COM SHS | 24477V105 | — | 425,000 shares | $19,992,000 |
| ANNEXON INC | COM | 03589W102 | — | 3,500,000 shares | $19,985,000 |
| ORUKA THERAPEUTICS INC | COM | 687604108 | — | 183,330 shares | $17,447,516 |
| MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 61559X104 | — | 855,813 shares | $16,662,679 |
| SAGIMET BIOSCIENCES INC | COM SER A | 786700104 | — | 2,029,933 shares | $15,691,382 |
| CONTINEUM THERAPEUTICS INC | CL A | 21217B100 | — | 921,481 shares | $15,103,074 |
| IMMIX BIOPHARMA INC | COM | 45258H106 | — | 1,277,642 shares | $13,172,489 |
| CLIMB BIO INC | COM | 28658R106 | — | 1,000,000 shares | $13,040,000 |
| AMYLYX PHARMACEUTICALS INC | COM | 03237H101 | — | 700,000 shares | $12,572,000 |
| NEKTAR THERAPEUTICS | COM NEW | 640268306 | — | 175,000 shares | $12,216,750 |
| NEUROGENE INC | COM | 64135M105 | — | 352,180 shares | $11,076,061 |
| LB PHARMACEUTICALS INC | COM SHS | 50180M108 | — | 317,221 shares | $10,295,408 |
| OPUS GENETICS INC | COM | 67577R102 | — | 1,970,187 shares | $8,097,469 |
| EUPRAXIA PHARMACEUTICALS INC | COM | 29842P105 | — | 1,200,000 shares | $7,932,000 |
| BRIGHT MINDS BIOSCIENCES INC | COM NEW | 10919W405 | — | 109,603 shares | $7,694,131 |
| INFLARX NV | COM | N44821101 | — | 3,046,557 shares | $6,824,288 |
| RELMADA THERAPEUTICS INC | COM | 75955J402 | — | 842,106 shares | $5,827,374 |
| JATT II ACQUISITION CORP | ORD SHS | G50765109 | — | 500,000 shares | $5,680,000 |
| CULLINAN THERAPEUTICS INC | COM | 230031106 | — | 300,000 shares | $5,463,000 |
| ALTIMMUNE INC | COM NEW | 02155H200 | — | 1,741,232 shares | $5,293,345 |
| AMANAT ACQUISITION CORP | CL A ORD | G0375M101 | — | 500,000 shares | $5,080,000 |
| REZOLUTE INC | COM NEW | 76200L309 | — | 951,809 shares | $4,949,407 |
| SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | — | 450,000 shares | $4,941,000 |
| PALISADE BIO INC | COM | 696389402 | — | 2,284,819 shares | $4,775,272 |
| EVOMMUNE INC | COM SHS | 30054Y107 | — | 325,000 shares | $4,319,250 |
| SCYNEXIS INC | COM | 811292309 | — | 944,292 shares | $3,843,268 |
| GALECTIN THERAPEUTICS INC | COM NEW | 363225202 | CALL | 800,000 shares | $3,712,000 |
| ENLIVEN THERAPEUTICS INC | COM | 29337E102 | — | 70,000 shares | $3,552,500 |
| HUMACYTE INC | COM | 44486Q103 | — | 3,750,000 shares | $2,926,500 |
| REIN THERAPEUTICS INC | COM NEW | 00887A204 | — | 2,575,000 shares | $2,678,000 |
| DBV TECHNOLOGIES S A | SPONSORED ADS | 23306J309 | — | 156,906 shares | $2,573,258 |
| ANAVEX LIFE SCIENCES CORP | COM NEW | 032797300 | CALL | 521,300 shares | $1,350,167 |
| PROMIS NEUROSCIENCES INC | COM SHS | 74346M505 | — | 86,150 shares | $1,133,734 |